鹽酸納美芬聯(lián)合曲克蘆丁腦蛋白水解物注射液治療新生兒缺氧缺血性腦病的臨床效果

龔梨林

【摘要】 目的：探討鹽酸納美芬聯(lián)合曲克蘆丁腦蛋白水解物注射液治療新生兒缺氧缺血性腦病的臨床效果。方法：選取2012年10月-2015年11月本院確診治療的缺氧缺血性腦病患兒100例，依據(jù)隨機(jī)分配原則分為美芬蛋白組和美芬組，每組50例。美芬組患兒給予常規(guī)基礎(chǔ)治療及鹽酸納美芬治療，美芬蛋白組患兒在此基礎(chǔ)上給予曲克蘆丁腦蛋白水解物注射液治療，采用神經(jīng)行為測定（NBNA）評分評估患兒的神經(jīng)功能，采用Gesell發(fā)育量表評估患兒智能發(fā)育情況，并統(tǒng)計(jì)分析患兒的臨床療效和不良反應(yīng)發(fā)生情況。結(jié)果：美芬蛋白組患兒治療總有效率、NBNA評分及DQ均明顯高于美芬組，差異均有統(tǒng)計(jì)學(xué)意義（P<0.05）；美芬蛋白組和美芬組患兒不良反應(yīng)發(fā)生率分別為16.00%、6.00%，兩組比較差異無統(tǒng)計(jì)學(xué)意義（P>0.05）。結(jié)論：鹽酸納美芬聯(lián)合曲克蘆丁腦蛋白水解物注射液治療可有效緩解新生兒缺氧缺血性腦病的臨床癥狀，提高患兒的臨床療效，且具有良好的安全性，值得臨床作進(jìn)一步推廣。

【關(guān)鍵詞】 新生兒； 缺氧缺血性腦?。?鹽酸納美芬； 曲克蘆丁腦蛋白水解物注射液

【Abstract】 Objective：To explore the clinical efficacy of Nalmefene Hydrochloride combined with Troxerutin and Cerebroprotein Hydrolysate Injection in treatment of newborn hypoxic ischemic encephalopathy.Method：100 children with hypoxic ischemic encephalopathy in our hospital from October 2012 to November 2015 were selected，they were randomly divided into Mefene-protein group and Mefene group，50 cases in each group.The Mefene group was given conventional treatment and Nalmefene Hydrochloride treatment，while the Mefene-protein group was additionally given Cerebroprotein Hydrolysate Injection treatment.Neonatal behavioral neurological assessment（NBNA） score was used to assess the neurological function，and the Gesell development scale was used to assess the intelligence development of the children，the clinical efficacy and adverse reactions of the patients were statistically analyzed.Result：The total effective rate，NBNA score and DQ of Mefene-protein group were significantly higher than those in Mefene group（P<0.05）.The incidence of adverse reactions was 16.00% in the Mefene-protein group and 6.00% in the Mefene group，the difference was no statistically significant（P>0.05）.Conclusion：Nalmefene Hydrochloride combined with Troxerutin and Cerebroprotein Hydrolysate Injection can effectively alleviate the clinical symptoms of neonatal hypoxic ischemic encephalopathy，improve the clinical efficacy of children，and has a good safety，it is worth of further promotion.

【Key words】 Newborn； Hypoxic ischemic encephalopathy； Nalmefene Hydrochloride； Troxerutin and Cerebroprotein Hydrolysate Injection

First-authors address：Fengcheng Peoples Hospital，F(xiàn)engcheng 331100，China

doi：10.3969/j.issn.1674-4985.2016.36.028

新生兒缺氧缺血性腦病是臨床上新生兒常見的一種臨床高危病癥，是圍生期新生兒因缺氧引起腦部病變所致，可導(dǎo)致意識模糊、驚厥、呼吸節(jié)律不齊等癥狀，嚴(yán)重影響患兒的身體健康[1]。目前，新生兒缺氧缺血性腦病臨床上多采用吸氧、保暖、降顱內(nèi)壓、止驚等基礎(chǔ)治療[2-4]，可有效緩解患兒的臨床癥狀，但由于新生兒體質(zhì)虛弱，導(dǎo)致療效欠佳，故如何提高患兒的臨床療效成為了廣大學(xué)者重點(diǎn)關(guān)注的問題。對此，本研究通過給予患兒鹽酸納美芬聯(lián)合曲克蘆丁腦蛋白水解物注射液治療，探討其對患兒的療效的影響及其安全性，現(xiàn)報(bào)道如下。

1 資料與方法endprint